Table 2.
Antihypertensive medications in patients eligible for 3-year follow-up
| Baseline (n = 1721) | 1 year (n = 1729) | 2 years (n = 1729) | 3 years (n = 1730) | P-valuea | |
|---|---|---|---|---|---|
| Antihypertensive medication classes | 4.5 ± 1.4 | 4.4 ± 1.4 | 4.4 ± 1.5 | 4.4 ± 1.5 | <0.001 |
| Beta-blockers (%) | 77.4 | 75.8 | 74.7 | 74.0 | <0.001 |
| ACE inhibitors (%) | 34.2 | 30.5 | 29.5 | 29.2 | <0.001 |
| Angiotensin receptor blockers (%) | 66.5 | 65.9 | 65.7 | 65.3 | 0.018 |
| Calcium channel blockers (%) | 77.6 | 76.4 | 76.5 | 76.2 | 0.071 |
| Diuretics (%) | 79.3 | 77.8 | 76.9 | 76.0 | <0.001 |
| Aldosterone antagonists (%) | 24.8 | 27.6 | 28.9 | 29.2 | <0.001 |
| Alpha-adrenergic blockers (%) | 35.1 | 33.1 | 32.4 | 32.4 | 0.006 |
| Direct-acting vasodilators (%) | 14.1 | 13.7 | 13.7 | 13.8 | 0.939 |
| Centrally-acting sympatholytics (%) | 38.8 | 35.6 | 35.0 | 34.3 | <0.001 |
| Direct renin inhibitors (%) | 6.2 | 4.9 | 4.7 | 4.4 | <0.001 |
a
Three years vs. baseline using the McNemar’s test for categorical variables and the paired t-test for number of anti-hypertensive medications.